Venous Thromboembolism
Tranexamic acid use may not increase thrombotic events in high-risk patients
Results published in The Journal of Bone & Joint Surgery showed the use of tranexamic acid during total joint arthroplasty did not increase the risk for thrombotic complications in patients with a history of venous thromboembolism.
Patient factors impact risk of venous thromboembolism after THA, TKA
According to published results, underlying patient factors may have a greater impact on risk of venous thromboembolism in patients undergoing total hip or knee arthroplasty compared with thromboprophylactic agents.
Substance abuse in OSA raises odds for cardiovascular, cerebrovascular events
HONOLULU — Young patients with obstructive sleep apnea faced heightened odds for major adverse cardiovascular and cerebrovascular events if they abused drugs, according to an abstract presented at the CHEST Annual Meeting.
Opioids carry increased risk for death vs NSAIDs in patients with rheumatoid arthritis
In patients with rheumatoid arthritis, NSAIDs and opioids demonstrate similar risks for major adverse cardiovascular events, while opioids exhibit higher rates of all-cause mortality and venous thromboembolism, according to data.
Common cancer therapies increase VTE risk for patients with cancer, COVID-19
Relative risk for venous thromboembolism appeared high among patients with COVID-19 and cancer who received specific cancer treatments, according to study results published in JAMA Oncology.
Abelacimab trial for AF stopped early due to ‘overwhelming’ reduction in bleeding
Anthos Therapeutics announced that the phase 2 AZALEA-TIMI 71 study was stopped early due to an “overwhelming reduction” in bleeding in patients with atrial fibrillation at high risk for stroke taking abelacimab vs. rivaroxaban.
ASH guidelines on thrombophilia testing ‘could change practice’
Thrombophilia is a known risk factor for venous thromboembolism, but the value of thrombophilia testing in guiding treatment decisions remains a topic of debate.
Incidence of cancer-associated thrombosis remains high over time, varies with therapy
Incidence of venous thromboembolism remained high among patients with cancer even as the treatment landscape has evolved over the past 16 years, according to data published in JAMA Network Open.
Aspirin, enoxaparin for VTE prophylaxis yield similar 90-day mortality rates after TJA
Investigators of this study found similar 90-day mortality rates for patients who underwent total joint arthroplasty with either aspirin or enoxaparin for venous thromboembolism prophylaxis.
Adults with atopic dermatitis face slightly elevated venous thromboembolism risk
An increased rate of venous thromboembolism is associated with atopic dermatitis in adults, although that increased risk is small, according to a study.